Answers are grounded in this paper and cite their sources.
Immune checkpoint therapies aiming to enhance T cell responses have revolutionized cancer immunotherapy. However, although a small fraction of patients develops durable anti-tumor responses, the majority of patients display only transient responses, underlying the need for finding auxiliary approaches. Tumor microenvironment poses a major metabolic barrier to efficient anti-tumor T cell activity. As it is now well accepted that metabolism regulates T cell fate and function, harnessing metabolism may be a new strategy to potentiate T cell-based immunotherapies.
No takes yet. Share an insight, caveat, or question.
Aksoylar et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: